Romidepsin (HDAC1/2 inhibitor), valproic acid (Class I HDAC inhibitor), or RGFP966 (HDAC3 inhibitor) can upregulate MHC class I expression and the expression of costimulatory molecules such as CD80 and CD86 in B-cell lymphomas (258). The gene discussed is HDAC3; the disease is B-cell non-Hodgkin lymphoma.